Enobia is pleased to partner with The National Organization of Rare Diseases in celebrating World Rare Disease Day on February 28th. We believe that partnering with patients is a key element of the drug development process. Since Enobia’s lead development program is for Hypophosphatasia, a rare bone disease affecting a few thousand patients worldwide, we rely on the knowledge, organization and collaboration of patient advocates, clinicians and researchers to help advance our program. We are proud to have provided financial and in kind support to groups such as NORD, CORD, MAGIC, Hypophosphatasie e.V., Hypophosphatasie Europe and US Soft Bones in the last year. We are delighted to partner with these groups on important initiatives and look forward to a long, collaborative relationship with the Hypophosphatasia community.